According to the Complaint, Array BioPharma Inc. is a fully integrated biopharmaceutical company focused on the discovery, development, and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.

This action stems from a proposed transaction announced on June 17, 2019, pursuant to which Array BioPharma Inc. will be acquired by Pfizer Inc.

On June 14, 2019, Array’s Board of Directors caused the Company to enter into an agreement and plan of merger with Pfizer.

On June 28, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction.

The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed
Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on July 26, 2019.